FasterCures supports Scott Gottlieb as FDA commissioner
There are several important opportunities for the U.S. Food and Drug Administration (FDA) to support its vital mission, including passage of the user fee agreements, innovations in clinical trials and medical product evaluation, more effective integration of patient perspectives, and new authorities to strengthen its workforce. Many news outlets reported today that the president is expected to nominate Scott Gottlieb as the next FDA commissioner. FasterCures, a Center of the Milken Institute, urges swift confirmation of Gottlieb so that he can begin the important work needed for FDA to fulfill its responsibility to protect the public’s health and ensure that patients have continued access to safe, effective and high-quality medical products. We have a long history of supporting initiatives aligned with FDA’s values of enhancing biomedical science through collaboration and speeding innovations in medical products, and we look forward to continuing this as we work with FDA leadership and staff.